Caribou Biosciences Inc

CRBU

Company Profile

  • Business description

    Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

  • Contact

    2929 7th Street
    Suite 105
    BerkeleyCA94710
    USA

    T: +1 510 982-6030

    https://www.cariboubio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    147

Stocks News & Analysis

stocks

Chart of the Week: Inflation fears dampen sentiment on retailers

Rising inflation is the fly in the ointment.
stocks

Here’s 3 Top Rated ASX shares for 2026

As we start the new year, let’s take a closer look at three compelling opportunities on the ASX
stocks

Undervalued Aussie e-commerce winner

Shares attractive due to near term profit margin increase and structural growth.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,046.507.000.08%
CAC 408,243.476.040.07%
DAX 4025,080.1042.16-0.17%
Dow JONES (US)49,272.53276.450.56%
FTSE 10010,021.3426.87-0.27%
HKSE26,149.31561.14-2.10%
NASDAQ23,434.53112.65-0.48%
Nikkei 22551,117.261,400.82-2.67%
NZX 50 Index13,716.861.840.01%
S&P 5006,915.974.96-0.07%
S&P/ASX 2008,720.802.70-0.03%
SSE Composite Index4,082.982.79-0.07%

Market Movers